We hypothesized that reprogramming the tumor myeloid compartment through HDAC inhibition prior to giving anti-PD-1 immunotherapy might facilitate CD8+ T cell tumor infiltration and anti-tumor activity. This evidence concerns the gene CD8A and neoplasm.